Ziconotide for treatment of severe chronic pain

@article{Schmidtko2010ZiconotideFT,
  title={Ziconotide for treatment of severe chronic pain},
  author={Achim Schmidtko and J{\"o}rn L{\"o}tsch and Rainer Freynhagen and Gerd Geisslinger},
  journal={The Lancet},
  year={2010},
  volume={375},
  pages={1569-1577}
}
View on Elsevier
alt.kompetenznetz-parkinson.de
271 Citations
Highly Influential Citations
11
Background Citations
114
Methods Citations
6
Results Citations
1

Figures from this paper

271 Citations

Citation Type

Citation Type

Intrathecal Ziconotide: A Review of Its Use in Patients with Chronic Pain Refractory to Other Systemic or Intrathecal Analgesics
TLDR
Intrathecal ziconotide provides a treatment option for patients with severe, unremitting pain who have failed to respond to other intensive analgesic regimens and for enhancing its efficacy and tolerability.
Ziconotide: a clinical update and pharmacologic review
  • J. Pope, T. Deer
  • Medicine, Biology
    Expert opinion on pharmacotherapy
  • 2013
TLDR
Ziconotide is a safe and effective strategy to treat chronic pain, although limitations remain, including a small therapeutic window, and low starting doses and slow incremental increases and long titration intervals may improve tolerability.
Intrathecal Administration of Ziconotide as a Potential Treatment for Chronic Migraines
TLDR
Ziconotide is proposed to have efficacy for chronic neuropathic pain, with a favorable lack of tolerance and chemical dependency, and is reported to have use for chronic refractory migraines.
Intracerebroventricular Pain Treatment with Analgesic Mixtures including Ziconotide for Intractable Pain.
TLDR
Using ziconotide by intracerebroventricular infusion seems safe and efficient, specifically for chronic neoplastic pain of cervicocephalic, thoracic, or diffuse origin and also for pain arising from a central neuropathic mechanism.
Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain
TLDR
The failure of previously tested antioxidants, neuroprotective agents, anticonvulsants and antidepressants as therapeutic or preventative strategies are discussed, and individualized, mechanism-based therapeutic options for CIPNP associated with each of the three main drug groups are suggested.
Pharmacogenetics of chronic pain management.
Intrathecal combination of ziconotide and morphine for refractory cancer pain: A rapidly acting and effective choice
Omega-Conotoxins as Experimental Tools and Therapeutics in Pain Management
TLDR
There remains a critical need to improve the convenience of peptide drug delivery methods, and reduce the number and severity of adverse effects associated with ω-conotoxin-based therapies, in the treatment of neuropathic pain.
Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials
TLDR
The results suggest that ziconotide is beneficial for pain reduction in chronic neuropathic pain, however, there remain some methodological issues that may call into question the validity of the results.
Intrathecal Ziconotide and Morphine for Pain Relief: A Case Series of Eight Patients with Refractory Cancer Pain, Including Five Cases of Neuropathic Pain
TLDR
Adding ziconotide to intrathecal opioid-based therapy in cancer patients with neuropathic pain inadequately controlled by intratheCal morphine alone is recommended on the basis of clinical experience.
...
...

References

SHOWING 1-10 OF 74 REFERENCES
Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
  • U. Klotz
  • Biology, Medicine
    International journal of clinical pharmacology and therapeutics
  • 2006
TLDR
Ziconotide is a new and valuable alternative analgesic for the acute and long-term treatment of severe pain, especially in patients refractory to opioids.
Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain
  • M. Wallace
  • Medicine, Biology
    Expert review of neurotherapeutics
  • 2006
TLDR
Ziconotide is a new nonopioid intrathecal agent recently approved for the treatment of chronic pain that blocks the N-type calcium channels located in the superficial dorsal horn of the spinal cord, resulting in potent analgesia.
Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
TLDR
Ziconotide provides significant pain relief to severe chronic pain sufferers who have failed to obtain relief from opiate therapy and no evidence of tolerance to ziconotide is seen in these patients, and is likely to be the first in a new class of neurological drugs: the N-type calcium channel blockers, or NCCBs.
Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
  • G. Miljanich
  • Biology, Medicine
    Current medicinal chemistry
  • 2004
TLDR
Ziconotide is a neuroactive peptide in the final stages of clinical development as a novel non-opioid treatment for severe chronic pain and will be the first in a new class of neurological drugs: the N-type calcium channel blockers, or NCCBs.
Ziconotide: an update and review.
TLDR
Ziconotide is a synthetic neuroactive peptide equivalent to the omega conotoxin MVIIA, a constituent of the venom of the fish-hunting marine snail Conus magus, and has a steep dose-response curve, a slow onset of action and a narrow margin of safety and responses to dose adjustments are slow.
Ziconotide, an Intrathecally Administered N‐Type Calcium Channel Antagonist for the Treatment of Chronic Pain
TLDR
In early clinical trials, frequent and severe psychiatric and central nervous system adverse effects were associated with rapid intrathecal infusion and frequent up‐titration, and patients with psychiatric symptoms are not candidates for this drug.
An effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotide.
Treatment challenges and complications with ziconotide monotherapy in established pump patients.
TLDR
Achieving adequate analgesia, reducing Ziconotide to mitigate adverse physiological effects, managing opioid withdrawal symptoms, and supportive psychological consultation were combined to achieve successful outcomes in two of three patients.
Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain
TLDR
Ziconotide is a conopeptide intrathecal analgesic which provides analgesia via binding to N-type voltage-sensitive calcium channels in the spinal cord and is approved by the US FDA for the management of severe chronic pain.
Formulary Forum: Intrathecal Ziconotide for Refractory Chronic Pain
TLDR
Ziconotide is a therapeutic option for treatment of severe chronic pain in patients who have exhausted all other agents, including intrathecal morphine, and for whom the potential benefit outweighs the risks of serious neuropsychiatric adverse effects and of having an implanted device.
...
...